-
BMS’ Opdivo combo approved in US for hepatocellular carcinoma
14 Apr 2025 11:16 GMT
The US Food and Drug Administration (FDA) has granted approval for Bristol … first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC), a primary … randomised Phase III CheckMate-9DW trial, in which the combination showed …
-
BMS gets another FDA okay for Opdivo/Yervoy combo
14 Apr 2025 12:25 GMT
… therapy for unresectable or metastatic hepatocellular carcinoma (HCC) – the most common form … open-label CheckMate-9DW trial.
In the trial, Opdivo/ … an option for HCC again after the drug was pulled … major feature of first-line treatment, with BMS' …
-
BMS receives FDA approval for immunotherapy combination in liver cancer
14 Apr 2025 12:16 GMT
… US Food and Drug Administration (FDA) to treat patients with hepatocellular carcinoma (HCC), the most common … stage, at which point effective treatment options are limited.
Opdivo plus … strength of evidence from the trial, especially considering the selection …
-
FDA OKs First-line Nivolumab + Ipilimumab in Advanced HCC
14 Apr 2025 05:42 GMT
… US Food and Drug Administration (FDA) has approved nivolumab … line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC). … early results from the trial, which were presented … will be available at Drugs@FDA.
Sharon Worcester, MA, …
-
BMS Immunotherapy Combo Gets Two FDA Nods for GI Cancers in Span of a Week
13 Apr 2025 15:14 GMT
… and Yervoy for treating advanced cases of hepatocellular carcinoma. In the … earlier line of treatment — after anti-androgen drugs and before … Pharmaceuticals developed to treat allergic reactions to insect bites, medications, and food, expanded its FDA …
-
Combination Therapy of Transarterial Chemoembolization, Lenvatinib, and PD-1 Inhibitors Achieves Significant Tumor Response in Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Report
12 Apr 2025 16:27 GMT
… initiation, the patient developed grade 1 hypertension … triple therapy for treating HCC with BDTT has … for advanced hepatocellular carcinoma patients. Front Pharmacol. 2021;12 … line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial …
-
Serum Osteopontin Enhances Hepatocellular Carcinoma Diagnosis and Predicts Anti-PD-L1 Immunotherapy Benefit
12 Apr 2025 16:23 GMT
… . Herein, we developed a multivariate logistic … CheckMate 040 (clinical trial number: NCT01658878) and … . Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients … guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018; …
-
Nivolumab With Ipilimumab Approved by FDA for Use in Hepatocellular Carcinoma
11 Apr 2025 22:44 GMT
… method of treatment for hepatocellular carcinoma (HCC), specifically in … the CHECKMATE-9DW trial (NCT04039607), which … 2 months).
The medication was well tolerated … drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-hepatocellular-carcinoma …
-
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
11 Apr 2025 20:11 GMT
… the only trial supporting an FDA approval to … treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC). … be adequate to treat mild to moderate … the research, development and commercialization of pharmaceutical products. All …
-
FDA Approves Nivolumab Plus Ipilimumab for Unresectable or Metastatic Hepatocellular Carcinoma
11 Apr 2025 16:31 GMT
… line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC). … phase 3 CheckMate 9DW trial (NCT04039607), which demonstrated … -drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-hepatocellular-carcinoma
…
About
© 1995-2025